The Cardiac Biomarkers Market size was valued at USD 18.20 Billion in 2023 and the total Cardiac Biomarkers Market revenue is expected to grow at a CAGR of 14.55 % from 2024 to 2030, reaching nearly USD 47.12 Billion by 2030.Cardiac Biomarkers Market Overview
Cardiac biomarkers are substances released into the bloodstream when the heart muscle is damaged or stressed. These biomarkers include enzymes, hormones, and proteins. Measuring these biomarkers help diagnose, assess risk, and manage conditions like acute coronary syndrome (ACS) and cardiac ischemia. In the United States, they're used to diagnose, assess risk, and manage acute coronary syndrome (ACS), a potentially life-threatening condition. ACS is a leading cause of death in the US, accounting for 625,000 hospital discharges annually.To know about the Research Methodology :- Request Free Sample Report Examples of cardiac biomarkers include: 1. Creatine kinase (CK) Also known as creatine phosphokinase (CPK), this muscle enzyme increases 3–4 hours after a heart attack and remains elevated for 3–4 days. This makes it useful for detecting re-infarction within 4–10 days of the initial attack. 2. Myoglobin This small oxygen-carrying protein found in the heart rises rapidly after a heart attack, making it a valuable biomarker for differential diagnosis. 3. Glycogen phosphorylase isoenzyme BB (GPBB) This enzyme is converted into a soluble form and released into the blood during ischemia. Levels of GPBB rise rapidly in myocardial infarction and unstable angina and is elevated 1–3 hours after ischemia. Cardiac Biomarkers is a market with a global footprint, transcending geographical boundaries. Consumers from various continents display interest in these supplements, rendering the market a widespread presence. The Cardiac Biomarkers industry report provides a comprehensive and detailed overview of the market, incorporating statistical data alongside current trends. This report delineates the Cardiac Biomarkers market landscape, encompassing dynamics, market segments, regional analysis, and the market position of top competitors.
Cardiac Biomarkers Market Dynamics
The burgeoning prevalence of cardiovascular diseases worldwide stands as a primary driver behind the growth of the cardiac biomarkers market. As heart-related ailments persist as leading causes of mortality, the necessity for accurate diagnostic tools like cardiac biomarkers intensifies. According to the World Health Organization (WHO), cardiovascular diseases account for approximately 17.9 million deaths globally each year, representing about 31% of all global deaths. Moreover, continuous advancements in biomarker technology enhance their precision, sensitivity, and specificity, thereby bolstering their efficacy in diagnosing various heart conditions. For instance, the development of high-sensitivity troponin assays has revolutionized the diagnosis of acute myocardial infarction, allowing for earlier detection and intervention. The cardiac biomarkers market have several constraints as the considerable cost associated with biomarker tests and diagnostic equipment, particularly inhibitory in regions with limited healthcare budgets these factors affect the growth of cardiac biomarkers Market. According to a report by the American Heart Association, the estimated direct and indirect costs of cardiovascular diseases and stroke in the United States alone total USD 351.2 billion annually. Furthermore, stringent regulatory requirements pose hurdles, often delaying the introduction of new biomarkers into the market. Additionally, in certain developing regions, inadequate awareness and healthcare infrastructure impede widespread adoption, exacerbating disparities in access to cardiovascular care. Emerging Trends in the Cardiac Biomarkers Market In tandem with advancements, the cardiac biomarkers market witnesses the emergence of transformative trends. The growing inclination towards personalized medicine, where treatment plans are tailored based on individual biomarker profiles, ushered in a new era of precision diagnostics and therapies. According to a study published in the Journal of the American College of Cardiology, personalized medicine approaches have shown promising results in improving outcomes for patients with cardiovascular diseases by targeting specific biomarkers. Concurrently, integration with artificial intelligence (AI) presents immense potential, as machine learning algorithms analyze biomarker data to deliver more accurate and predictive diagnostic insights. The AI in the healthcare market, which was valued at $4.9 billion in 2020, is projected to reach USD 45.2 billion by 2026, reflecting the significant investment and interest in AI-driven solutions. Moreover, ongoing research endeavors focus on the discovery of novel biomarkers that offer comprehensive insights into cardiovascular health, promising further innovation in the field. As such, collaborations between pharmaceutical companies, diagnostic firms, and research institutions are accelerating the development and commercialization of new biomarkers, underscoring the dynamic nature of the cardiac biomarkers market. For example, recent studies have identified new biomarkers like microRNAs and long non-coding RNAs, which could provide deeper insights into heart disease mechanisms. This growth underscores the dynamic nature of the Cardiac Biomarkers Market, driven by advancements in technology and the continuous pursuit of improved diagnostic methods. Furthermore, collaborations between pharmaceutical companies, diagnostic firms, and research institutions are accelerating the development and commercialization of new biomarkers, further propelling market growth.
Cardiac Biomarkers Market Segment Analysis
Based on the Type, the cardiac biomarkers market is segmented by type into CK-MB, Troponin, Myoglobin, BNP and NT-proBNP, Ischemia Modified Albumin (IMA), and others. Among these, Troponin dominates the market, accounting for the largest share due to its high specificity and sensitivity in diagnosing myocardial infarction. Troponin tests, especially high-sensitivity troponin (hs-cTn) assays, have become the gold standard in clinical settings for early detection of acute myocardial infarction. According to market data, Troponin assays accounted for over 40% of the total market share in 2023. BNP and NT-proBNP also hold a significant share, primarily used for diagnosing and managing heart failure. These biomarkers provide critical insights into cardiac function, aiding in the effective management of cardiovascular conditions.Based on the Application, the application segment of the cardiac biomarkers market includes Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and others. The Myocardial Infarction subsegment is the dominant application area, driven by the high incidence of heart attacks globally and the crucial role of cardiac biomarkers in early and accurate diagnosis. In 2023, the myocardial infarction segment held approximately 45% of the market share. Acute Coronary Syndrome and Congestive Heart Failure represent significant portions of the Cardiac Biomarkers Market, as biomarkers are essential in diagnosing and managing these conditions. The increasing prevalence of cardiovascular diseases, along with the growing adoption of biomarkers for early diagnosis, underpins the dominance of these application areas. Based on the End-Use, the end-use segment of Cardiac Biomarkers Market is divided into Laboratory Testing and Point of Care. Laboratory Testing dominates this segment, capturing around 60% of the market share in 2023. This dominance is attributed to the high accuracy and comprehensive nature of laboratory-based assays, which are essential for detailed cardiac analysis. However, the Point of Care segment is growing rapidly due to its convenience and the increasing demand for rapid diagnostic solutions, particularly in emergency settings. The Point of Care segment is expected to grow at a higher CAGR over the forecast period, driven by advancements in portable testing devices and a shift towards immediate patient care. This growth is facilitated by the increasing adoption of point-of-care testing in both developed and developing regions, aiming to provide timely and effective treatment for cardiac events.
Cardiac Biomarkers Market Regional Insight
In 2023, North America led the global cardiac biomarkers market, capturing the largest revenue share of over 41.1%. This dominance is attributed to a well-developed healthcare system and the high adoption rate of cardiac biomarkers for diagnostic and predictive purposes. The rising geriatric population in the region significantly drives the demand for biomarker testing, particularly for conditions like acute myocardial infarction. The presence of major players such as Quidel Corporation and Danaher Corporation further contributes to market growth. Additionally, the World Health Organization (WHO) reports that 77 million adults over 18 years old have type 2 diabetes in North America, with 25 million more being prediabetic. This high prevalence of diabetes increases the risk of cardiovascular diseases, adding pressure on the healthcare system and boosting the demand for cardiac biomarkers. The Asia Pacific region is expected to witness the fastest growth, with expected CAGR of 16.0% during the forecast period. This rapid expansion is driven by the increasing affordability of advanced cardiac tests, the modernization of healthcare systems, and rising disposable incomes. The growing incidence of cardiovascular diseases (CVDs) in the region has heightened the need for improved diagnostics. Government funding for targeted disease research and increased healthcare expenditure also play crucial roles in this growth. India, in particular, has a higher prevalence of CVDs compared to other developing countries, further propelling the demand for cardiac biomarker diagnostics in the Cardiac Biomarkers Market. The high disease burden in the Asia Pacific is expected to continue to boost the demand for cardiac biomarker diagnostics in the Cardiac Biomarkers Market, facilitating the diagnosis, evaluation, and management of CVDs. For instance, in January 2023, Indian multinational pharmaceutical company Cipla Inc. launched Cippoint, a diagnostic device offering point-of-care testing for various health conditions. Approved by the European In-Vitro Diagnostic Device Directive, Cippoint covers a wide range of testing parameters, including diabetes, cardiac markers, fertility, infectious diseases, inflammation, thyroid function, metabolic markers, and coagulation markers. This innovation exemplifies the region's progress in enhancing diagnostic capabilities and meeting the growing healthcare needs in the Cardiac Biomarkers Market.
Cardiac Biomarkers Market Scope: Inquire Before Buying
Global Cardiac Biomarkers Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2023 Market Size in 2023: US $ 18.20 Bn. Forecast Period 2024 to 2030 CAGR: 14.55% Market Size in 2030: US $ 47.12 Bn. Segments Covered: by Type CK-MB Troponin Myoglobin BNP and NT-proBNP Ischemia Modified Albumin (IMF) Others by Application Myocardial Infarction Congestive Heart Failure Acute Coronary Syndrome Atherosclerosis Others by End Use Laboratory Testing Point of Care Cardiac Biomarkers Market, by region
North America (United States, Canada, and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Russia, and Rest of Europe) Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa) South America (Brazil, Argentina, Rest of South America)Leading Cardiac Biomarkers Manufacturers include:
1. Abbott (Abbott Park, Illinois, USA) 2. Quidel Corporation (San Diego, California, USA) 3. Siemens Healthcare GmbH (Erlangen, Germany) 4. F. Hoffmann-La Roche Ltd. (Basel, Switzerland) 5. Danaher (Washington, D.C., USA) 6. BIOMÉRIEUX (Marcy-l'Étoile, France) 7. Bio-Rad Laboratories, Inc. (Hercules, California, USA) 8. Randox Laboratories Ltd. (Crumlin, Northern Ireland, UK) 9. Creative Diagnostics (Shirley, New York, USA) 10. Life Diagnostics (West Chester, Pennsylvania, USA) 11. Others Frequently Asked Questions: 1] What is the growth rate of the Global Cardiac Biomarkers Market? Ans. The Global Cardiac Biomarkers Market is growing at a significant rate of 14.55 % during the forecast period. 2] Which region is expected to dominate the Global Cardiac Biomarkers Market? Ans. North America is expected to dominate the Cardiac Biomarkers Market during the forecast period. 3] What is the expected Global Cardiac Biomarkers Market size by 2030? Ans. The Cardiac Biomarkers Market size is expected to reach USD 47.12 Bn by 2030. 4] Which are the top players in the Global Cardiac Biomarkers Market? Ans. The major top players in the Global Cardiac Biomarkers Market are Abbott, Quidel Corporation, Siemens Healthcare GmbH, and others. 5] What are the factors driving the Global Cardiac Biomarkers Market growth? Ans. The burgeoning prevalence of cardiovascular diseases worldwide stands as a primary driver behind the growth of the cardiac biomarkers market. 6] Which country held the largest Global Cardiac Biomarkers Market share in 2023? Ans. The United States held the largest Cardiac Biomarkers Market share in 2023.
1. Cardiac Biomarkers Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Cardiac Biomarkers Market: Dynamics 2.1. Cardiac Biomarkers Market Trends by Region 2.1.1. North America Cardiac Biomarkers Market Trends 2.1.2. Europe Cardiac Biomarkers Market Trends 2.1.3. Asia Pacific Cardiac Biomarkers Market Trends 2.1.4. Middle East and Africa Cardiac Biomarkers Market Trends 2.1.5. South America Cardiac Biomarkers Market Trends 2.2. Cardiac Biomarkers Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Cardiac Biomarkers Market Drivers 2.2.1.2. North America Cardiac Biomarkers Market Restraints 2.2.1.3. North America Cardiac Biomarkers Market Opportunities 2.2.1.4. North America Cardiac Biomarkers Market Challenges 2.2.2. Europe 2.2.2.1. Europe Cardiac Biomarkers Market Drivers 2.2.2.2. Europe Cardiac Biomarkers Market Restraints 2.2.2.3. Europe Cardiac Biomarkers Market Opportunities 2.2.2.4. Europe Cardiac Biomarkers Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Cardiac Biomarkers Market Drivers 2.2.3.2. Asia Pacific Cardiac Biomarkers Market Restraints 2.2.3.3. Asia Pacific Cardiac Biomarkers Market Opportunities 2.2.3.4. Asia Pacific Cardiac Biomarkers Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Cardiac Biomarkers Market Drivers 2.2.4.2. Middle East and Africa Cardiac Biomarkers Market Restraints 2.2.4.3. Middle East and Africa Cardiac Biomarkers Market Opportunities 2.2.4.4. Middle East and Africa Cardiac Biomarkers Market Challenges 2.2.5. South America 2.2.5.1. South America Cardiac Biomarkers Market Drivers 2.2.5.2. South America Cardiac Biomarkers Market Restraints 2.2.5.3. South America Cardiac Biomarkers Market Opportunities 2.2.5.4. South America Cardiac Biomarkers Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Cardiac Biomarkers Industry 2.8. Analysis of Government Schemes and Initiatives For Cardiac Biomarkers Industry 2.9. Cardiac Biomarkers Market Trade Analysis 2.10. The Global Pandemic Impact on Cardiac Biomarkers Market 3. Cardiac Biomarkers Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2023-2030 3.1. Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 3.1.1. CK-MB 3.1.2. Troponin 3.1.3. Myoglobin 3.1.4. BNP and NT-proBNP 3.1.5. Ischemia Modified Albumin (IMF) 3.1.6. Others 3.2. Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 3.2.1. Myocardial Infarction 3.2.2. Congestive Heart Failure 3.2.3. Acute Coronary Syndrome 3.2.4. Atherosclerosis 3.2.5. Others 3.3. Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 3.3.1. Laboratory Testing 3.3.2. Point of Care 3.4. Cardiac Biomarkers Market Size and Forecast, by Region (2023-2030) 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Middle East and Africa 3.4.5. South America 4. North America Cardiac Biomarkers Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 4.1. North America Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 4.1.1. CK-MB 4.1.2. Troponin 4.1.3. Myoglobin 4.1.4. BNP and NT-proBNP 4.1.5. Ischemia Modified Albumin (IMF) 4.1.6. Others 4.2. North America Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 4.2.1. Myocardial Infarction 4.2.2. Congestive Heart Failure 4.2.3. Acute Coronary Syndrome 4.2.4. Atherosclerosis 4.2.5. Others 4.3. North America Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 4.3.1. Laboratory Testing 4.3.2. Point of Care 4.4. North America Cardiac Biomarkers Market Size and Forecast, by Country (2023-2030) 4.4.1. United States 4.4.1.1. United States Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 4.4.1.1.1. CK-MB 4.4.1.1.2. Troponin 4.4.1.1.3. Myoglobin 4.4.1.1.4. BNP and NT-proBNP 4.4.1.1.5. Ischemia Modified Albumin (IMF) 4.4.1.1.6. Others 4.4.1.2. United States Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 4.4.1.2.1. Myocardial Infarction 4.4.1.2.2. Congestive Heart Failure 4.4.1.2.3. Acute Coronary Syndrome 4.4.1.2.4. Atherosclerosis 4.4.1.2.5. Others 4.4.1.3. United States Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 4.4.1.3.1. Laboratory Testing 4.4.1.3.2. Point of Care 4.4.2. Canada 4.4.2.1. Canada Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 4.4.2.1.1. CK-MB 4.4.2.1.2. Troponin 4.4.2.1.3. Myoglobin 4.4.2.1.4. BNP and NT-proBNP 4.4.2.1.5. Ischemia Modified Albumin (IMF) 4.4.2.1.6. Others 4.4.2.2. Canada Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 4.4.2.2.1. Myocardial Infarction 4.4.2.2.2. Congestive Heart Failure 4.4.2.2.3. Acute Coronary Syndrome 4.4.2.2.4. Atherosclerosis 4.4.2.2.5. Others 4.4.2.3. Canada Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 4.4.2.3.1. Laboratory Testing 4.4.2.3.2. Point of Care 4.4.3. Mexico 4.4.3.1. Mexico Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 4.4.3.1.1. CK-MB 4.4.3.1.2. Troponin 4.4.3.1.3. Myoglobin 4.4.3.1.4. BNP and NT-proBNP 4.4.3.1.5. Ischemia Modified Albumin (IMF) 4.4.3.1.6. Others 4.4.3.2. Mexico Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 4.4.3.2.1. Myocardial Infarction 4.4.3.2.2. Congestive Heart Failure 4.4.3.2.3. Acute Coronary Syndrome 4.4.3.2.4. Atherosclerosis 4.4.3.2.5. Others 4.4.3.3. Mexico Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 4.4.3.3.1. Laboratory Testing 4.4.3.3.2. Point of Care 5. Europe Cardiac Biomarkers Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 5.1. Europe Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 5.2. Europe Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 5.3. Europe Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 5.4. Europe Cardiac Biomarkers Market Size and Forecast, by Country (2023-2030) 5.4.1. United Kingdom 5.4.1.1. United Kingdom Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 5.4.1.2. United Kingdom Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 5.4.1.3. United Kingdom Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 5.4.2. France 5.4.2.1. France Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 5.4.2.2. France Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 5.4.2.3. France Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 5.4.3. Germany 5.4.3.1. Germany Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 5.4.3.2. Germany Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 5.4.3.3. Germany Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 5.4.4. Italy 5.4.4.1. Italy Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 5.4.4.2. Italy Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 5.4.4.3. Italy Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 5.4.5. Spain 5.4.5.1. Spain Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 5.4.5.2. Spain Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 5.4.5.3. Spain Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 5.4.6. Sweden 5.4.6.1. Sweden Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 5.4.6.2. Sweden Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 5.4.6.3. Sweden Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 5.4.7. Austria 5.4.7.1. Austria Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 5.4.7.2. Austria Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 5.4.7.3. Austria Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 5.4.8. Rest of Europe 5.4.8.1. Rest of Europe Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 5.4.8.2. Rest of Europe Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 5.4.8.3. Rest of Europe Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 6. Asia Pacific Cardiac Biomarkers Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 6.1. Asia Pacific Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 6.2. Asia Pacific Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 6.3. Asia Pacific Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 6.4. Asia Pacific Cardiac Biomarkers Market Size and Forecast, by Country (2023-2030) 6.4.1. China 6.4.1.1. China Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 6.4.1.2. China Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 6.4.1.3. China Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 6.4.2. S Korea 6.4.2.1. S Korea Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 6.4.2.2. S Korea Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 6.4.2.3. S Korea Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 6.4.3. Japan 6.4.3.1. Japan Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 6.4.3.2. Japan Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 6.4.3.3. Japan Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 6.4.4. India 6.4.4.1. India Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 6.4.4.2. India Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 6.4.4.3. India Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 6.4.5. Australia 6.4.5.1. Australia Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 6.4.5.2. Australia Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 6.4.5.3. Australia Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 6.4.6. Indonesia 6.4.6.1. Indonesia Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 6.4.6.2. Indonesia Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 6.4.6.3. Indonesia Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 6.4.7. Malaysia 6.4.7.1. Malaysia Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 6.4.7.2. Malaysia Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 6.4.7.3. Malaysia Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 6.4.8. Vietnam 6.4.8.1. Vietnam Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 6.4.8.2. Vietnam Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 6.4.8.3. Vietnam Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 6.4.9. Taiwan 6.4.9.1. Taiwan Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 6.4.9.2. Taiwan Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 6.4.9.3. Taiwan Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 6.4.10. Rest of Asia Pacific 6.4.10.1. Rest of Asia Pacific Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 6.4.10.2. Rest of Asia Pacific Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 6.4.10.3. Rest of Asia Pacific Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 7. Middle East and Africa Cardiac Biomarkers Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 7.1. Middle East and Africa Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 7.2. Middle East and Africa Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 7.3. Middle East and Africa Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 7.4. Middle East and Africa Cardiac Biomarkers Market Size and Forecast, by Country (2023-2030) 7.4.1. South Africa 7.4.1.1. South Africa Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 7.4.1.2. South Africa Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 7.4.1.3. South Africa Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 7.4.2. GCC 7.4.2.1. GCC Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 7.4.2.2. GCC Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 7.4.2.3. GCC Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 7.4.3. Nigeria 7.4.3.1. Nigeria Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 7.4.3.2. Nigeria Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 7.4.3.3. Nigeria Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 7.4.4. Rest of ME&A 7.4.4.1. Rest of ME&A Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 7.4.4.2. Rest of ME&A Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 7.4.4.3. Rest of ME&A Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 8. South America Cardiac Biomarkers Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 8.1. South America Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 8.2. South America Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 8.3. South America Cardiac Biomarkers Market Size and Forecast, by End Use(2023-2030) 8.4. South America Cardiac Biomarkers Market Size and Forecast, by Country (2023-2030) 8.4.1. Brazil 8.4.1.1. Brazil Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 8.4.1.2. Brazil Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 8.4.1.3. Brazil Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 8.4.2. Argentina 8.4.2.1. Argentina Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 8.4.2.2. Argentina Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 8.4.2.3. Argentina Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 8.4.3. Rest Of South America 8.4.3.1. Rest Of South America Cardiac Biomarkers Market Size and Forecast, by Type (2023-2030) 8.4.3.2. Rest Of South America Cardiac Biomarkers Market Size and Forecast, by Application (2023-2030) 8.4.3.3. Rest Of South America Cardiac Biomarkers Market Size and Forecast, by End Use (2023-2030) 9. Global Cardiac Biomarkers Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Cardiac Biomarkers Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Abbott (Abbott Park, Illinois, USA) 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Quidel Corporation (San Diego, California, USA) 10.3. Siemens Healthcare GmbH (Erlangen, Germany) 10.4. F. Hoffmann-La Roche Ltd. (Basel, Switzerland) 10.5. Danaher (Washington, D.C., USA) 10.6. BIOMÉRIEUX (Marcy-l'Étoile, France) 10.7. Bio-Rad Laboratories, Inc. (Hercules, California, USA) 10.8. Randox Laboratories Ltd. (Crumlin, Northern Ireland, UK) 10.9. Creative Diagnostics (Shirley, New York, USA) 10.10. Life Diagnostics (West Chester, Pennsylvania, USA) 10.11. Others 11. Key Findings 12. Industry Recommendations 13. Cardiac Biomarkers Market: Research Methodology 14. Terms and Glossary
